Our innovative preclinical solutions empower your drug development journey with cutting-edge analytics and insights from inception to preclinical stages.
We help you navigate complex trial phases efficiently with data-driven methods & strategies tailored to Phase I-III trials for accelerated drug development.
Maximize your market potential and optimize your commercial strategies with our advanced analytical methods, data science, and tailored commercialization solutions for data-driven commercial success.
Harness the power of real-world data and real-world evidence to gather insights and shape future drug development cycles for enhanced efficacy and regulatory compliance.
Craft optimal trial designs with our advanced analytical methods to enhance efficiency and increase the probability of success throughout your drug’s lifecycle.
Empower your trial delivery by transforming trial designs into actionable strategies with our data-driven approach to ensure seamless delivery and successful outcomes.
We offer tailored analytics solutions for your specialized or niche projects enabling you to optimize both efficiency and precision in drug development.
Experience the future of flexible strategic partnerships with Analytics on Demand, providing adaptive and innovative solutions that transcend traditional models to achieve unparalleled operational excellence.
Maximize efficiency and outcomes with our project-based services, delivering specialized expertise, end-to-end biometrics, and focused solutions for unique projects, ensuring timely completion and exceptional results.
Cytel's software platform enables precise trial design and simulation, utilizing adaptive and Bayesian tools to optimize protocols and accelerate drug development with confidence and efficiency.
Trial Implementation and Decision Support Software
Our unique software package streamlines trial implementation with intuitive solutions for protocol development, randomization, and patient management, optimizing operational efficiency and ensuring study success.
Discover comprehensive solutions for every stage of development — from data and regulatory strategies to Phase I-IV clinical trials, market access planning, and beyond.
Learn about our rich history, visionary leadership, and core values. Our mission and vision drive us to deliver excellence in drug development globally.
Join our innovative team at Cytel! Explore exciting career opportunities in data science and statistics, analytical methods, and regulatory strategy. Advance the future of human health with us.
Our innovative preclinical solutions empower your drug development journey with cutting-edge analytics and insights from inception to preclinical stages.
We help you navigate complex trial phases efficiently with data-driven methods & strategies tailored to Phase I-III trials for accelerated drug development.
Maximize your market potential and optimize your commercial strategies with our advanced analytical methods, data science, and tailored commercialization solutions for data-driven commercial success.
Harness the power of real-world data and real-world evidence to gather insights and shape future drug development cycles for enhanced efficacy and regulatory compliance.
Craft optimal trial designs with our advanced analytical methods to enhance efficiency and increase the probability of success throughout your drug’s lifecycle.
Empower your trial delivery by transforming trial designs into actionable strategies with our data-driven approach to ensure seamless delivery and successful outcomes.
We offer tailored analytics solutions for your specialized or niche projects enabling you to optimize both efficiency and precision in drug development.
Experience the future of flexible strategic partnerships with Analytics on Demand, providing adaptive and innovative solutions that transcend traditional models to achieve unparalleled operational excellence.
Maximize efficiency and outcomes with our project-based services, delivering specialized expertise, end-to-end biometrics, and focused solutions for unique projects, ensuring timely completion and exceptional results.
Cytel's software platform enables precise trial design and simulation, utilizing adaptive and Bayesian tools to optimize protocols and accelerate drug development with confidence and efficiency.
Our unique software package streamlines trial implementation with intuitive solutions for protocol development, randomization, and patient management, optimizing operational efficiency and ensuring study success.
Learn about our rich history, visionary leadership, and core values. Our mission and vision drive us to deliver excellence in drug development globally.
Join our innovative team at Cytel! Explore exciting career opportunities in data science and statistics, analytical methods, and regulatory strategy. Advance the future of human health with us.
For nearly 20 years, stève consultants has been dedicated to supporting its clients in obtaining and maintaining reimbursement for their health products (drugs, vaccines, medical devices, invitro assay) in France.
Multidisciplinary team
Our team of experts, with diverse backgrounds (health-authorities, pharmaceutical industry, academic…), brings a multidisciplinary approach covering all the issues to meet our clients’ expectations.
Local market expertise
Since our integration into Cytel, our teams have been contributing to the understanding of local requirements to ensure success in the Market access strategy of our clients, the preparation of EU joint clinical evaluationsor in the realization of multi-country projects including France.
Experience across all therapeutic areas
We work in all therapeutic areas, with a strong focus on innovation, and are particularly experienced in oncology, hematology, immunology and infectious, neurological, metabolic as well as rare diseases.
Market Access
Our market access experts have worked on more than 500 dossiers submitted to the Haute Autorité de Santé (HAS) and offer support in:
Benchmarking and gap analysis, HTA requirement fulfillment, local pricing and reimbursement strategy, roadmap, advisory boards
Early access program request (funding before marketing authorization or during price negotiation for innovative drugs) including preparation of the early access meetings with Health Authorities, and writing of the dossier
Writing and submission of reimbursement and economic dossiers to Health Authorities
Support throughout the local HTA process, notably during contradictory phase if needed
Follow-up of additional information request by health-authorities (post-registration study, re-evaluation dossier…)
Our experts are also involved in global projects providing:
Local inputs on payer requirements to reinforce market access strategy: PICO analysis, study design, early advice, literature reviews…
With more than 50 model developments or adaptations and 20 evaluations submitted to Haute Autorité de Santé (HAS), our HEOR team supports you with:
The design and drafting of cost-effectiveness dossiers for French authorities (CEESP).
The development of robust health economic models to support strategic decision-making and demonstrate the value of healthcare products.
The preparation of scientific communications and health economic value materials to support value demonstration and product positioning.
The adaptation of international models to the French context, incorporating local specificities to optimize pricing and reimbursement strategies.
We also contribute to global projects, ensuring alignment with French requirements and supporting local adaptations to strengthen the overall international strategy.
Our RWE experts have conducted more than 150 studies using the French National Healthcare claims database (SNDS), alone or linked with other clinical data sources (registries, primary data collection, clinical trials…). SNDS is exhaustive of the French population and can be processed through several accesses (DCIR, ESND, PMSI). Our dedicated team supports you in defining and implementing your real-world data generation strategy for studies with objectives in:
Epidemiology: descriptive epidemiology, target population, patient characteristics, natural history of the disease, risk factors, etc.
Pharmacoepidemiology: real-world effectiveness, safety, adherence, etc.
Clinical practices: patient management, treatment sequences, misuse, care pathways, etc.
Health economics: healthcare resource utilization, costs, burden of disease, etc.
Our experts are highly experienced in statistical methods applied to RWE data, as well as machine learning and data visualization techniques (propensity scores, matching, predictive models, random forests, clustering, treatment sequence analysis, etc.).
We also take part in multi-country observational studies by providing key data from France, one of the leading European countries with a comprehensive, population-wide healthcare database.
Steve Consultants is now part Cytel. We take pride in the teams and relationships we’ve built over the years, and we’re committed to ensuring your drug development project moves seamlessly with local expertise for all your market access needs. The faces you’ve come to trust and the offices you’re familiar with remain unchanged.
Our locations
Lyon (Head office) | 30 rue Narcisse Bertholey | 69600 Oullins – France
Paris | 64-66 Rue des Archives | 75003 Paris – France
As part of its activities, stève consultants carries out epidemiological and medico-economic research projects using the databases of the National Health Data System ( SNDS ). These medico-administrative databases are created for reimbursement purposes and contain, exhaustively for the French population, data relating to hospitalizations, consumption of care provided in the community and deaths. As the SNDS databases are for administrative purposes, they do not contain medical reports or the results of examinations carried out.
Interested in talking strategy with some of our experts? Fill in the form below and we'll get back to you as soon as possible to set up a call or meeting.
EN 
FR 
